Cancer Research Horizons is the innovation arm of Cancer Research UK
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 18, 2023--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Cancer Research Horizons, the innovation engine at the core of one of the world’s largest private funders of cancer research, Cancer Research UK (CRUK), today announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma Solutions Library of Libraries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230718140133/en/
“Teaming up with Cancer Research Horizons to support exploratory drug discovery efforts, validating and de-risking biological targets has the potential to be groundbreaking for patients,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Cancer Research Horizons acts as a conduit between academia and industry, with our collaboration enabling early-stage antibody identification through access to our ‘Library of Libraries.’ With two mission-driven organizations aligning behind innovative technology solutions to improve health to make the world a better place, the opportunity to identify new biotherapeutics offers tremendous hope to those who need it most.”
“We’re delighted to partner with Twist Bioscience, an exciting technology platform company who will enhance our antibody discovery capabilities with their highly diverse phage display libraries,” said Hamish Ryder, CEO of Therapeutic Innovation at Cancer Research Horizons. “We look forward to using this technology to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients, in collaboration with our academic and industrial partners.”
Under the terms of the agreement, Cancer Research Horizons will license Twist’s Library of Libraries, an expansive collection of synthesized antibody libraries designed based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of antibody drug targets, for a period of five years. Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.
About Cancer Research Horizons
Cancer Research Horizons is the innovation arm of Cancer Research UK – one of the world’s largest charitable funders of cancer research. We bring together world-leading minds, bold ideas and the right partners to bridge the gap between research and introducing new therapeutics into the market. We focus on the riskier, more profound ideas that can lead to true innovation.
By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, licensing and collaboration, spin-out creation, and offer a full spectrum of drug discovery and clinical capabilities. With access to Cancer Research UK’s network of 4,000 exceptional researchers, and £300+ million of annual research spend, we’re a powerful partner in the fight to conquer cancer. Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered. To date, we’ve played an instrumental role in forming over 60 spin-out companies and helped to bring 11 cancer drugs to market. For more information and to get in touch with the team, visit cancerresearchhorizons.com.
About Twist Biopharma Solutions (The Biologics Discovery and Optimization Division of Twist Bioscience)
Twist Biopharma Solutions combines high-throughput DNA synthesis technology, deep expertise in antibody engineering and in vivo, in vitro and in silico discovery methods to provide end-to-end antibody discovery solutions across the preclinical continuum and tailored to our partner’s specific needs. By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries with discovery beginning with either in vivo or in vitro diversity. Our Library of Libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development. Additionally, in vivo discovery approaches including single B cell screening and hybridoma discovery enable parallel paths where multiple technology methods can be leveraged to create a panel of highly diverse antibody leads. Our automated screening and panning processes enable us to identify high affinity leads that our partners can move forward into the clinic. We also offer supporting development capabilities, including IgG conversion, expression, purification, biophysical characterization, and functional characterization.
For more information visit: https://www.twistbioscience.com/products/antibody-discovery/twist-bioscience-and-abveris
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including statements regarding the potential success of the collaboration and potential future revenue from any assets sold or transferred, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s workforce reduction, transition of production to the Factory of the Future and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions caused by the COVID-19 pandemic or otherwise; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230718140133/en/
For Twist Bioscience:
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com
For Cancer Research Horizons:
Tim Bodicoat
tim.bodicoat@cancer.org.uk
Source: Twist Bioscience Corporation
